Hypertension is one of the primary risk factors for heart disease and stroke, the leading causes of death due to its high prevalence all around the globe. Approximately 7.5 million deaths worldwide occur due to hypertension and predicted to increase to 1.56 billion adults with high blood pressure in 2030. The main objective of this research work was to conduct Preformulation analysis of Metoprolol tartrate ,beta-blocker antihypertensive medicine in order to produce a stable, robust system for effective management of hypertension. Preformulation is the study of the chemical and physical properties of the drug components prior to the compounding process of the formulation. The purpose of the study is to understand the nature and characteristics of each component and to optimize conditions of the dosage form manufacture. Metoprolol tartrate is rapidly absorbed from both gastric and intestinal regions, after oral administration. Metoprolol Tartrate microparticles were prepared with varying concentrations of rate retarding polymers such as Ethyl cellulose, Eudragit RL100, HPMC and solvents such as Ethanol and DCM using solvent evaporation technique to enable sustained release delivery system. The Preformulated microspheres were evaluated for physiochemical parameters. Fourier Transform-Infrared (FTIR) spectral analysis of drug and polymers revealed the absence of drug-polymer interactions and further confirmed by DSC thermo grams. The prepared microspheres of Metoprolol Tartrate reduce the need for multiple dosing and provide improved patient compliance.